Free Trial
NASDAQ:INMB

INmune Bio (INMB) Stock Price, News & Analysis

INmune Bio logo
$5.85
-0.10 (-1.68%)
(As of 10/31/2024 ET)

About INmune Bio Stock (NASDAQ:INMB)

Key Stats

Today's Range
$5.67
$5.98
50-Day Range
$4.83
$7.06
52-Week Range
$4.78
$14.74
Volume
168,812 shs
Average Volume
163,310 shs
Market Capitalization
$115.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00
Consensus Rating
Buy

Company Overview

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
50th Percentile Overall Score

INMB MarketRank™: 

INmune Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 627th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    INmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    INmune Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about INmune Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for INmune Bio are expected to grow in the coming year, from ($2.14) to ($1.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of INmune Bio is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of INmune Bio is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    INmune Bio has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about INmune Bio's valuation and earnings.
  • Percentage of Shares Shorted

    14.32% of the outstanding shares of INmune Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    INmune Bio has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in INmune Bio has recently increased by 5.60%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    INmune Bio does not currently pay a dividend.

  • Dividend Growth

    INmune Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.32% of the outstanding shares of INmune Bio have been sold short.
  • Short Interest Ratio / Days to Cover

    INmune Bio has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in INmune Bio has recently increased by 5.60%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    INmune Bio has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for INmune Bio this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for INMB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added INmune Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, INmune Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $200,087.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    35.20% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.72% of the stock of INmune Bio is held by institutions.

  • Read more about INmune Bio's insider trading history.
Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INMB Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
INmune Bio to host webinar on cognitive testing using EMACC, CDR-SB
INmune Bio announces publication of XPro1595 data in Cell Reports
See More Headlines

INMB Stock Analysis - Frequently Asked Questions

INmune Bio's stock was trading at $11.26 at the beginning of the year. Since then, INMB stock has decreased by 48.0% and is now trading at $5.85.
View the best growth stocks for 2024 here
.

INmune Bio, Inc. (NASDAQ:INMB) posted its earnings results on Thursday, August, 1st. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative trailing twelve-month return on equity of 103.56%.

Top institutional investors of INmune Bio include Fermata Advisors LLC (0.22%) and Financial Advocates Investment Management (0.07%). Insiders that own company stock include Raymond Joseph Tesi, David J Moss, Timothy J Schroeder, Scott Juda and Mark William Lowdell.
View institutional ownership trends
.

Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

Last Earnings
8/01/2024
Today
10/31/2024
Next Earnings (Confirmed)
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INMB
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$22.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+241.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-30,010,000.00
Net Margins
-26,333.59%
Pretax Margin
-44,402.35%

Debt

Sales & Book Value

Annual Sales
$85,000.00
Book Value
$2.07 per share

Miscellaneous

Free Float
12,805,000
Market Cap
$115.60 million
Optionable
Optionable
Beta
1.85
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:INMB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners